NHS EED (economic evaluations)
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#1
(lowering blood pressure or lowering-blood-pressure or blood pressure lowering).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui] #2 (hypertensi$ or antihypertensi$ or anti-hypertensi$).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui Usually the choice of comparators is governed by the scope of the model. Impact of assumptions adopted when deciding upon comparators should be assessed as part of the structural uncertainty analysis
Is there a discussion around feasible options or justification for the exclusion of feasible options?
The choice of comparators affects results and should be determined by the decision problem, not by data availability. All feasible and practical strategies as determined by the scope of the model should be considered. Constraining the range of strategies should be justified
Time horizon
Is the time horizon of the model justified and sufficient to reflect all important differences between options?
Time horizon of the model should be long enough to capture relevant differences in outcomes across strategies (lifetime Most common sources of data include population-based epidemiological studies, control arms of trials or literature
Has (all) methods and assumptions used to derive transition probabilities and intervention effects been described/justified?
Attention should be given to the use of transition probabilities and rates; conversion of transition probabilities from one time unit to another should be done through rates and never presented as percentages
Has parameters relating to the effectiveness of interventions derived from observational studies been controlled for confounding?
If results of meta-analyses were used as data sources then consider how potential confounders are addressed; consider the likelihood of increased heterogeneity resulting from residual confounding and from other biases across studies. Efficacy derived from RCT may have to be adjusted for compliance to reflect real-world effectiveness. Effectiveness derived from observational studies must be adjusted for confounding (e.g., using multivariate regression techniques or propensity scoring). Adjustment for timevarying confounding (confounders that simultaneously act as intermediate steps in the pathway between intervention and outcome) require special methods such as marginal structural analysis or gestimation. When results from observational studies are used in the model, causal graphs can be used to explicitly state causal assumptions
Has the quality of the data been assessed appropriately? Sources of data and data limitations are expected to be discussed Has expert opinion been used, are the methods described and justified? An expectation that strengths and limitations of assumptions adopted should be included
Utilities
Are the utilities incorporated into the model appropriate? methods used to obtain utility weights and methodology used to transform health estate estimates into quality of life scores
Is the source for the utility weights referenced? Sources of data and data limitations are expected to be discussed
Cycle length and half cycle correction
Has the choice of cycle length been justified? It should be based on the clinical problem and remaining life expectancy
Has the use of a half cycle correction been stated? Any assumption adopted is expected to be disclosed
Resources/ costs
Are the costs incorporated into the model justified and sources described? Sources of data and data limitations are expected to be discussed Has discount rates been reported and justified given the target decision-maker?
Patient heterogeneity
Has patient heterogeneity been considered?
For example, in a cohort model states need to be homogeneous to observed or unobserved characteristics affecting transition probabilities to observed or unobserved characteristics affecting transition probabilities
Parameter precision
Has mean values and distributions around the mean and the source and rationale for the supporting evidence been clearly described for each parameter included in the model?
Sources of data and data limitations are expected to be discussed Has a Probabilistic Sensitivity Analysis (PSA) been included?
The specific distribution (e.g. Beta, normal, lognormal) as well as its parameters should be disclosed. When PSA is performed without an accompanying EVPI, options for presenting results include CEAC and distributions of net monetary benefit or net health benefit. When more than two comparators are involved, curves for each comparator should be plotted on the same graph.
Has correlation among parameters been assessed? Lack of evidence on correlation among parameters should not lead to an assumption of independence among parameters
If model calibration was used to derive parameters, has the uncertainty around calibrated values been tested using DSA or PSA?
Calibration is commonly used to estimate parameters or adjust estimated values such as overall and disease specific mortality and event incidence rates
Structural uncertainty
Has a discussion about the inclusion/exclusion of assumptions affecting the structure of the model been included? (refers to potentially relevant comparators, health states and recurrent events or any other assumption affecting the structure of the model)
For example: i) health states and the strategies adopted following the recurrence of events; ii) length of treatment effects; iii) types of adverse effects included; iv) duration of treatment effects; v) time dependency of probabilities (in a time dependent utility, the cost of delaying treatment as a function of the time a patient has remained in an untreated acute pathological state); vi) prognostic implications of surrogate end points; vii) clinical events; viii) comparators. Although these structural assumptions are not typically quantified, it is uncertain whether they express reality accurately and for that reason they should be assessed as part of structural uncertainty analysis 
